CN116825604A - 样品处理系统和由其执行的方法 - Google Patents
样品处理系统和由其执行的方法 Download PDFInfo
- Publication number
- CN116825604A CN116825604A CN202310699080.3A CN202310699080A CN116825604A CN 116825604 A CN116825604 A CN 116825604A CN 202310699080 A CN202310699080 A CN 202310699080A CN 116825604 A CN116825604 A CN 116825604A
- Authority
- CN
- China
- Prior art keywords
- sample
- aliquot
- analyzer
- mass spectrometer
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 225
- 238000012545 processing Methods 0.000 title claims abstract description 182
- 238000001514 detection method Methods 0.000 claims abstract description 67
- 230000003287 optical effect Effects 0.000 claims abstract description 34
- 239000012491 analyte Substances 0.000 claims description 183
- 238000006243 chemical reaction Methods 0.000 claims description 164
- 238000004458 analytical method Methods 0.000 claims description 133
- 230000008569 process Effects 0.000 claims description 93
- 238000012546 transfer Methods 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000000090 biomarker Substances 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 238000003556 assay Methods 0.000 abstract description 28
- 239000000523 sample Substances 0.000 description 905
- 239000003153 chemical reaction reagent Substances 0.000 description 179
- 238000003018 immunoassay Methods 0.000 description 101
- 150000002500 ions Chemical class 0.000 description 97
- 238000012360 testing method Methods 0.000 description 65
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 60
- 238000004949 mass spectrometry Methods 0.000 description 47
- 238000002360 preparation method Methods 0.000 description 34
- 229960003604 testosterone Drugs 0.000 description 32
- 238000011534 incubation Methods 0.000 description 31
- 238000005406 washing Methods 0.000 description 27
- 229940079593 drug Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 238000010828 elution Methods 0.000 description 22
- 239000006228 supernatant Substances 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 20
- 239000000126 substance Substances 0.000 description 17
- 239000002245 particle Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 230000005291 magnetic effect Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 12
- 229940025084 amphetamine Drugs 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 238000005040 ion trap Methods 0.000 description 11
- 239000006249 magnetic particle Substances 0.000 description 11
- 238000007885 magnetic separation Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000005298 paramagnetic effect Effects 0.000 description 10
- 238000013467 fragmentation Methods 0.000 description 9
- 238000006062 fragmentation reaction Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 230000000984 immunochemical effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- -1 pleural fluid Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000006920 protein precipitation Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000002470 solid-phase micro-extraction Methods 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000013102 re-test Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 206010013654 Drug abuse Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012470 diluted sample Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 238000004401 flow injection analysis Methods 0.000 description 4
- 238000013101 initial test Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000002552 multiple reaction monitoring Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000002310 reflectometry Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 238000011166 aliquoting Methods 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000003255 drug test Methods 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000004630 mental health Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 238000006276 transfer reaction Methods 0.000 description 3
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 2
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 230000001780 adrenocortical effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000000766 differential mobility spectroscopy Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001211 electron capture detection Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 2
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000005464 sample preparation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- RAJWOBJTTGJROA-UHFFFAOYSA-N (5alpha)-androstane-3,17-dione Natural products C1C(=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 RAJWOBJTTGJROA-UHFFFAOYSA-N 0.000 description 1
- FMFKNGWZEQOWNK-UHFFFAOYSA-N 1-butoxypropan-2-yl 2-(2,4,5-trichlorophenoxy)propanoate Chemical compound CCCCOCC(C)OC(=O)C(C)OC1=CC(Cl)=C(Cl)C=C1Cl FMFKNGWZEQOWNK-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- RAJWOBJTTGJROA-WZNAKSSCSA-N 5alpha-androstane-3,17-dione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 RAJWOBJTTGJROA-WZNAKSSCSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ULFUTCYGWMQVIO-PCVRPHSVSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentano Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 ULFUTCYGWMQVIO-PCVRPHSVSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002897 diene group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- AWZOLILCOUMRDG-UHFFFAOYSA-N edifenphos Chemical compound C=1C=CC=CC=1SP(=O)(OCC)SC1=CC=CC=C1 AWZOLILCOUMRDG-UHFFFAOYSA-N 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003312 immunocapture Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 108010079003 sodium-influx-stimulating peptide Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
- G01N27/622—Ion mobility spectrometry
- G01N27/624—Differential mobility spectrometry [DMS]; Field asymmetric-waveform ion mobility spectrometry [FAIMS]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00584—Control arrangements for automatic analysers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N35/1095—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices for supplying the samples to flow-through analysers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0031—Step by step routines describing the use of the apparatus
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0036—Step by step routines describing the handling of the data generated during a measurement
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/025—Detectors specially adapted to particle spectrometers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
- H01J49/0409—Sample holders or containers
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/26—Mass spectrometers or separator tubes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509601P | 2017-05-22 | 2017-05-22 | |
| US62/509,601 | 2017-05-22 | ||
| US201762607773P | 2017-12-19 | 2017-12-19 | |
| US62/607,773 | 2017-12-19 | ||
| PCT/US2018/033927 WO2018217778A1 (en) | 2017-05-22 | 2018-05-22 | Integrated sample processing system with multiple detection capability |
| CN201880049114.1A CN110959185B (zh) | 2017-05-22 | 2018-05-22 | 具有多种检测能力的集成样品处理系统 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880049114.1A Division CN110959185B (zh) | 2017-05-22 | 2018-05-22 | 具有多种检测能力的集成样品处理系统 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116825604A true CN116825604A (zh) | 2023-09-29 |
Family
ID=62621016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880049114.1A Active CN110959185B (zh) | 2017-05-22 | 2018-05-22 | 具有多种检测能力的集成样品处理系统 |
| CN202310699080.3A Pending CN116825604A (zh) | 2017-05-22 | 2018-05-22 | 样品处理系统和由其执行的方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880049114.1A Active CN110959185B (zh) | 2017-05-22 | 2018-05-22 | 具有多种检测能力的集成样品处理系统 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11402386B2 (enExample) |
| EP (2) | EP3631839B1 (enExample) |
| JP (3) | JP2020521958A (enExample) |
| CN (2) | CN110959185B (enExample) |
| WO (1) | WO2018217778A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959185B (zh) * | 2017-05-22 | 2023-06-30 | 拜克门寇尔特公司 | 具有多种检测能力的集成样品处理系统 |
| US11125738B2 (en) | 2018-11-06 | 2021-09-21 | Thermo Finnigan Llc | Blood sample analysis systems and methods |
| EP3899548A1 (en) * | 2018-12-21 | 2021-10-27 | DH Technologies Development Pte. Ltd. | Method for measuring testosterone using lc-msms |
| WO2020225971A1 (ja) | 2019-05-08 | 2020-11-12 | 株式会社日立ハイテク | 自動分析装置の前処理方法 |
| CN114667590B (zh) * | 2019-09-25 | 2025-03-25 | 印地安纳大学理事会 | 用于脉冲模式电荷检测质谱法的设备和方法 |
| CN114502942B (zh) | 2019-09-30 | 2025-10-10 | Dh科技发展私人贸易有限公司 | 用于在质谱法系统和方法中使用的具有内部取样的取样探针 |
| WO2021072186A1 (en) | 2019-10-10 | 2021-04-15 | The Trustees Of Indiana University | System and method for identifying, selecting and purifying particles |
| CN113777332B (zh) * | 2020-06-09 | 2024-06-18 | 深圳迈瑞生物医疗电子股份有限公司 | 免疫分析仪和自身免疫分析方法 |
| JP2024501976A (ja) * | 2020-12-30 | 2024-01-17 | ベックマン コールター， インコーポレイテッド | 単一の較正剤を用いた臨床検査室自動化システム |
| US20240255473A1 (en) * | 2021-06-03 | 2024-08-01 | Dh Technologies Development Pte. Ltd. | System and methods for sample processing with mass spectrometry incorporating magnetic beads |
| CN114047345B (zh) * | 2021-11-09 | 2022-09-09 | 中元汇吉生物技术股份有限公司 | 一种样本优先调度方法、调度系统及检测系统 |
| EP4430382A1 (en) | 2021-11-12 | 2024-09-18 | Beckman Coulter, Inc. | System and methods for surface enhanced raman spectroscopy |
| CN116413253B (zh) * | 2023-03-15 | 2025-10-10 | 宁波海尔施智造有限公司 | 一种人乳头瘤病毒检测试剂及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58628B2 (ja) * | 1976-08-17 | 1983-01-07 | 株式会社島津製作所 | 自動分折装置 |
| US20030027216A1 (en) | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
| US6746648B1 (en) | 2000-06-15 | 2004-06-08 | Beckman Coulter, Inc. | Method and system for transporting and storing multiple reagent packs and reagent packs used therein |
| US6520755B1 (en) | 2000-10-10 | 2003-02-18 | Beckman Coulter, Inc. | Fluid-moving device with integrated valve |
| US6843481B1 (en) | 2000-10-10 | 2005-01-18 | Beckman Coulter, Inc. | Fluid-moving device with a clearance seal |
| US7128874B2 (en) | 2001-01-26 | 2006-10-31 | Beckman Coulter, Inc. | Method and system for picking and placing vessels |
| US6790412B2 (en) | 2001-02-06 | 2004-09-14 | Beckman Coulter, Inc. | Bulk vessel feeder |
| US7217391B2 (en) | 2001-03-16 | 2007-05-15 | Beckman Coulter, Inc. | Rotary incubation station for immunoassay systems |
| US6790413B2 (en) | 2001-05-03 | 2004-09-14 | Beckman Coulter, Inc. | Sample presentation unit |
| US7632686B2 (en) | 2002-10-03 | 2009-12-15 | Anderson Forschung Group | High sensitivity quantitation of peptides by mass spectrometry |
| US20060159587A1 (en) * | 2005-01-19 | 2006-07-20 | Beckman Coulter, Inc. | Automated clinical analyzer with dual level storage and access |
| JP2007000687A (ja) * | 2005-06-21 | 2007-01-11 | Shimadzu Corp | 生体試料中のペプチド分析方法及び装置 |
| ATE495447T1 (de) | 2006-07-03 | 2011-01-15 | Univ Johns Hopkins | Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie |
| JP2010175355A (ja) * | 2009-01-29 | 2010-08-12 | Hitachi High-Technologies Corp | 自動分析装置 |
| WO2010092958A1 (ja) | 2009-02-10 | 2010-08-19 | 株式会社日立ハイテクノロジーズ | 質量分析技術を用いた免疫分析方法および免疫分析システム |
| EP2412020B1 (en) * | 2009-03-24 | 2020-09-30 | University Of Chicago | Slip chip device and methods |
| EP3096147B1 (en) * | 2009-07-29 | 2023-12-20 | Hitachi High-Tech Corporation | Automatic analyzer |
| WO2012058632A1 (en) * | 2010-10-29 | 2012-05-03 | Thermo Fisher Scientific Oy | Automated system for sample preparation and analysis |
| EP2466308B1 (en) | 2010-12-14 | 2018-02-07 | Universitätsmedizin Greifswald Körperschaft des Öffentlichen Rechts Institut für Immunologie und Transfusionsmedizin Abteilung Immunologie | Immunoassay device and use of the device (immunoassay) |
| WO2012170549A1 (en) | 2011-06-06 | 2012-12-13 | Waters Technologies Corporation | Compositions, methods, and kits for quantifying target analytes in a sample |
| EP2745113B1 (en) * | 2011-08-16 | 2017-03-22 | Evotec (München) GmbH | Markers for susceptibility to an inhibitor of an src-family kinase |
| US9074236B2 (en) * | 2012-05-01 | 2015-07-07 | Oxoid Limited | Apparatus and methods for microbial identification by mass spectrometry |
| HK1209835A1 (en) | 2012-06-26 | 2016-04-08 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| WO2014152939A1 (en) | 2013-03-14 | 2014-09-25 | President And Fellows Of Harvard College | Methods and systems for identifying a physiological state of a target cell |
| WO2015105883A1 (en) | 2014-01-07 | 2015-07-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Apolipoprotein c biomarkers and methods for cholesterol efflux and cardiovascular health |
| GB2550631B (en) * | 2014-07-07 | 2020-07-29 | Hitachi High Tech Corp | Analysis device and analysis method |
| JP2016156675A (ja) * | 2015-02-24 | 2016-09-01 | 株式会社日立ハイテクノロジーズ | 自動分析装置及び分析方法 |
| TW201713775A (zh) * | 2015-06-25 | 2017-04-16 | 亞斯科生物科學公司 | 用於自複雜的異源群集中分析微生物品系、預測及識別其機能性關係及交互作用，且依據前述選擇並合成微生物系集之方法、裝置及系統 |
| CN110959185B (zh) | 2017-05-22 | 2023-06-30 | 拜克门寇尔特公司 | 具有多种检测能力的集成样品处理系统 |
-
2018
- 2018-05-22 CN CN201880049114.1A patent/CN110959185B/zh active Active
- 2018-05-22 WO PCT/US2018/033927 patent/WO2018217778A1/en not_active Ceased
- 2018-05-22 JP JP2019564473A patent/JP2020521958A/ja not_active Withdrawn
- 2018-05-22 EP EP18731643.5A patent/EP3631839B1/en active Active
- 2018-05-22 CN CN202310699080.3A patent/CN116825604A/zh active Pending
- 2018-05-22 US US16/616,052 patent/US11402386B2/en active Active
- 2018-05-22 EP EP24166653.6A patent/EP4411387A3/en active Pending
-
2022
- 2022-07-25 US US17/814,530 patent/US11988670B2/en active Active
-
2023
- 2023-03-10 JP JP2023037413A patent/JP7594618B2/ja active Active
-
2024
- 2024-04-09 US US18/630,611 patent/US20250027950A1/en active Pending
- 2024-07-16 JP JP2024113092A patent/JP2024133264A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018217778A1 (en) | 2018-11-29 |
| CN110959185A (zh) | 2020-04-03 |
| US20230011115A1 (en) | 2023-01-12 |
| JP2020521958A (ja) | 2020-07-27 |
| EP3631839A1 (en) | 2020-04-08 |
| US20250027950A1 (en) | 2025-01-23 |
| EP3631839B1 (en) | 2024-04-03 |
| US20210003586A1 (en) | 2021-01-07 |
| JP2023060337A (ja) | 2023-04-27 |
| EP4411387A3 (en) | 2024-11-13 |
| CN110959185B (zh) | 2023-06-30 |
| JP2024133264A (ja) | 2024-10-01 |
| EP4411387A2 (en) | 2024-08-07 |
| JP7594618B2 (ja) | 2024-12-04 |
| US11402386B2 (en) | 2022-08-02 |
| US11988670B2 (en) | 2024-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7594618B2 (ja) | 複数の検出能力を有する統合試料処理システム | |
| US12379370B2 (en) | Integrated sample processing system with variable workflows | |
| CN107085118B (zh) | 用于样品制备和分析的自动化系统和方法 | |
| US10585089B2 (en) | Analysis device and analysis method | |
| US20250155448A1 (en) | Identification and quantitation of insulin-like growth factor-i variants by mass spectrometry | |
| US20240061001A1 (en) | Clinical laboratory automation system with single calibrator | |
| US20240420939A1 (en) | Ultra high throughput screening combined with definitive testing in a single sample preparation step | |
| US20230333130A1 (en) | System and Method for Disposing of a Reaction Vessel of a Mass Spectrometry System | |
| WO2024057238A1 (en) | Single tube sample preparation and calibration for both screening and quantification of analytes | |
| WO2024206847A1 (en) | Methods for quantitation of adiponectin by mass spectrometry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |